Press Release<< Back
Esperion Therapeutics to Provide Fourth Quarter and Full Year ETC-1002 Program Updates and Financial Results
The call can be accessed by dialing (877) 831-3840 (domestic) or (253) 237-1184 (international) five minutes prior to the start of the call and providing access code 78833282. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the Esperion website at www.esperion.com. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for two weeks.
Esperion's Commitment to Cardiometabolic Disease Esperion is committed to improving the lives of patients with cardiometabolic diseases. The Esperion team leverages its understanding of, and experience with, key biological pathways to discover and develop innovative therapies for the treatment of patients with hypercholesterolemia who have uncontrolled cholesterol levels despite the use of currently available therapies. Esperion has assembled a portfolio of programs including one product candidate in late-stage clinical evaluation (ETC-1002) and two preclinical product candidates.
FOR FURTHER INFORMATION PLEASE CONTACT:
Elliot Fox W2O Group212.257.6724 firstname.lastname@example.org Investor Contact: Mindy Lowe Esperion Therapeutics, Inc.734.887.3903 email@example.com Source: Esperion Therapeutics, Inc.
News Provided by Acquire Media